Evidence map›Paper›PMID 25209843›Full record

ArticleAnnals of hematology2015

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.

Peter Valent, Jörg Berger, Sabine Cerny-Reiterer, Barbara Peter, Gregor Eisenwort, Gregor Hoermann, Leonhard Müllauer, Christine Mannhalter, Michael Steurer, Peter Bettelheim and 2 more

Abstract readCase Reports
In one paragraph

Article in Annals of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Mastocytosis.Nature reviews. Disease primers · 2025
    Review
  3. Detection ofInternational journal of molecular sciences · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Peter ValentDepartment of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria, peter.valent@meduniwien.ac.at.
Jörg Berger
Sabine Cerny-Reiterer
Barbara Peter
Gregor Eisenwort
Gregor Hoermann
Leonhard Müllauer
Christine Mannhalter
Michael Steurer
Peter Bettelheim
Hans-Peter Horny
Michel Arock
Medical University of Vienna · ATLudwig Boltzmann Cluster for Cardiovascular Research · ATÉcole Normale Supérieure Paris-Saclay · FRInnsbruck Medical University · ATKrankenhaus der Elisabethinen · ATLudwig-Maximilians-Universität München · DE

Funding

Austrian Science Fund FWF F 4704
6 · The paper itself

Abstract

Mast cell leukemia (MCL) is a rare, life-threatening malignancy defined by a substantial increase in neoplastic mast cells (MCs) in bone marrow (BM) smears, drug-resistance, and a poor prognosis. In most patients, the survival time is less than 1 year. However, exceptional cases may present with a less malignant course. We report on a 49-year-old female patient with MCL diagnosed in 2013. In February 2013, first symptoms, including flushing, headache, and diarrhea, were recorded. In addition, mild anemia was detected. The disease was characterized by a massive increase in well-granulated, mature, and often spindle-shaped MCs (80 %) in BM smears. The serum tryptase level amounted to 332 ng/mL. Like in most other MCL patients, no skin lesions were detected. However, unlike in other patients, tryptase levels remained stable, and no other signs or symptoms of MCL-induced organ damage were found. Sequencing studies revealed an isolated S476I point mutation in KIT but no mutation in codon 816. The patient received histamine receptor blockers but refused cytoreductive therapy. After 9 months, still no progression or organ damage was detected. However, progression with transformation to acute MCL occurred after 12 months. We propose that the chronic type of MCL with stable conditions, absence of organ damage, and a mature MC morphology is recognized as a distinct entity that should be distinguished from the acute variant of MCL.

Indexed as

Mutation, MissenseBone Marrow ExaminationCell ProliferationChronic DiseaseFemaleHumansLeukemia, Mast-CellMast CellsMiddle AgedProtein Kinase InhibitorsProto-Oncogene Proteins c-kitProtein Kinase InhibitorsProto-Oncogene Proteins c-kit

Identifiers

PMID25209843
PMCPMC4896380
OpenAlexW2013726895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.